Through use of selective antagonists, Linz et al. mechanistically demonstrated that attenuation of respiratory depression in cebranopadol can be attributed to NOP receptor agonism which counteracts side effects resulting from MOR agonism [77]. Here, OPRM1 is linked to Respiratory insufficiency due to muscle weakness.